Shilajit for Heart and Vascular Health After Menopause. What the Research Shows.

Quick answer: Across several human studies, shilajit improved the cardiovascular markers that track heart and vascular health. LDL fell. HDL rose. Triglycerides fell. Inflammatory markers fell. Oxidative damage, one of the root mechanisms behind lipid-driven cardiovascular risk, was cut by more than half in one trial. This article covers what each study measured, what it found, and where the honest limits of the evidence stand. No trial has positioned shilajit as a cardiovascular disease treatment, and neither do we.

What happens to the cardiovascular system at menopause

Most conversations about menopause start with hot flashes and bone density. The cardiovascular story is just as important, and it often unfolds quietly in the years right after the last period.

Estrogen ran lipid metabolism throughout a woman's reproductive years. It kept LDL cholesterol lower and HDL cholesterol higher. It supported the production of nitric oxide in the walls of blood vessels, the chemical signal that tells arteries to relax and stay flexible. It participated in lipid processing in the liver, moderating how much LDL circulates in the bloodstream.

When estrogen signaling drops at menopause, the lipid picture shifts. LDL rises. HDL falls. Triglycerides often climb. Arteries become less elastic. The cardiovascular risk profile that builds in the post-menopausal years is largely driven by this estrogen-decline mechanism. Salt intake and lifestyle choices matter, but they are not the whole story for a woman whose numbers changed the year her periods ended.

This is the terrain shilajit and the fulvic acid in it have been studied against.

The lipid and endothelial trial

The central piece of evidence for cardiovascular markers is a 12-week randomized controlled trial by Niranjan and colleagues. It enrolled 40 adults with type 2 diabetes and measured a comprehensive panel of cardiovascular health markers before and after.

The trial was double-blind and placebo-controlled, which is the appropriate standard for this kind of question.

Here is what the group taking shilajit showed compared to placebo by the end of 12 weeks.

LDL cholesterol fell 13 percent. Total cholesterol fell 21 percent. Triglycerides fell 16 percent. HDL cholesterol, the protective form, rose 14 percent. The inflammatory marker hsCRP fell. The oxidative damage marker MDA fell.

Endothelial function also improved. The Reflection Index, which measures how well artery walls respond to the heart's demand for blood flow, moved from minus 2.29 at baseline to minus 8.61. Endothelial function is one of the clearest measures of vascular health. The endothelium is the lining of your blood vessels. When it works well, it responds to demand by signaling the artery to relax and expand, using nitric oxide as the messenger. When endothelial function is impaired, vessels stay rigid regardless of what the body needs.

One important context note for this study. It was a small trial in a diabetic population, and it was published in a smaller Indian journal without a PubMed listing. Read it accordingly. The direction across every marker was favorable. It is the most comprehensive cardiovascular marker trial on shilajit to date, but it is not a large-scale cardiovascular outcomes study, and the lipid improvements cannot be extrapolated as if they were from a phase 3 drug trial.

Why oxidative stress is the heart health mechanism most people miss

The second key study approaches cardiovascular health from the oxidative angle, and it is published in one of the most credible journals in metabolic medicine.

A 2003 trial published in Diabetes Care, the peer-reviewed journal of the American Diabetes Association, enrolled 61 people with diabetes on a stable medication regimen. Shilajit was given at 500 mg twice daily for 30 days.

The marker tracked was MDA, which measures oxidative damage in the body. It fell by more than half over the 30-day period, from 15.56 to 6.52. The antioxidant enzyme catalase rose.

This matters for cardiovascular health because LDL cholesterol becomes dangerous largely when it gets oxidized. Oxidized LDL is the form that accumulates in blood vessel walls and contributes to plaque formation. Cutting the marker of oxidative damage is not a peripheral finding. It is working on one of the upstream mechanisms behind cardiovascular risk.

The adaptogen picture is also visible in this data. The authors noted that the body's demand on certain antioxidant enzymes appeared to drop, as if the burden placed on the oxidative defense system decreased overall. That is what adaptive mitochondrial support looks like in a biomarker panel.

A baseline picture in healthy adults

A third study adds context from a different angle. Published in the journal Ancient Science of Life in 2003, Sharma and colleagues looked at shilajit over 45 days in healthy adults who were not managing a specific condition.

This was an open-label study, a lower level of evidence than a randomized controlled trial. But what it found is consistent with the pattern across the other data. Total cholesterol fell. Triglycerides fell. HDL rose. Antioxidant status improved. Blood pressure stayed stable throughout.

The stable blood pressure finding is a useful safety marker for this population. The study was not measuring people with elevated pressure, and nothing shifted in either direction.

The nitric oxide signal from the bone trial

There is a secondary finding from a different trial that points in the same vascular direction.

The 2022 Pingali trial at Nizam's Institute of Medical Sciences was a 48-week randomized, double-blind, placebo-controlled trial in postmenopausal women. It was designed to study bone mineral density in women with osteopenia. Among the markers the researchers tracked was nitric oxide, because nitric oxide is involved in bone metabolism.

Nitric oxide rose 50 to 60 percent in the women taking shilajit, while the placebo group showed no comparable change.

Nitric oxide is the same signal the Niranjan trial showed improvement in through the endothelial function measurement. It is the molecule that keeps arteries responsive and flexible. A 50 to 60 percent rise in a postmenopausal population is a meaningful vascular finding, even in a trial designed for a different primary outcome.

A more recent PubMed-indexed trial

A 2025 randomized controlled trial indexed in PubMed enrolled 166 adults at elevated metabolic risk and studied a combination of chromium, Phyllanthus emblica, and shilajit alongside an exercise and diet program.

One important honesty note. Shilajit was one of several active ingredients in this trial, and exercise and diet were co-interventions. Isolating shilajit's contribution from this design is not possible.

What the trial found across all interventions together was modest improvements in vascular function, insulin sensitivity, lipid markers, and body composition.

The value of this study is not as a clean shilajit-alone lipid trial. It is as the most recently published, PubMed-indexed human trial in a cardiovascular and metabolic context that included shilajit, confirming that the directional signals are consistent with what earlier trials found.

What the evidence adds up to

The honest summary across these studies is a consistent pattern of improved cardiovascular health markers.

Cholesterol markers moved in the right direction in two separate studies. Inflammatory markers fell. Oxidative stress, one of the upstream mechanisms behind lipid-driven cardiovascular risk, was cut by more than half in the Diabetes Care trial. Endothelial function improved. Nitric oxide rose substantially. These findings are independent of each other, from different populations and study designs, and they point the same direction.

No human trial has studied shilajit as a cardiovascular disease treatment or measured hard outcomes like heart attacks or strokes. That ceiling is real. What the evidence supports is overall cardiovascular and vascular health, working on the mechanisms that cardiovascular risk builds on. The honest language around the evidence is support, not treatment.

Why this matters specifically at menopause

The reason this evidence matters more for postmenopausal women than for the general population is the estrogen-decline backdrop.

The risk factors shilajit has been shown to improve, rising LDL, falling HDL, oxidative accumulation in the blood, declining nitric oxide, impaired endothelial function, all accelerate in the years right after menopause because of what the drop in estrogen signaling does to lipid metabolism and vascular function. This is not a coincidence. It is the same mechanism.

Shilajit is not a hormone and does not add estrogen. The fulvic acid in shilajit supports the body's own estrogen signaling and addresses the oxidative environment that rises when that signaling is lost. That is the mechanism through which the vascular markers improve.

For women who are concerned about the estrogen angle, the research has addressed this directly. The fulvic acid in shilajit has been tested on MCF-7 breast cancer cells, the cells that are sensitive to estrogen, and it killed those cells while leaving healthy tissue alone. This does not feed estrogen-sensitive tissue. The evidence points the other direction.

Safety

Across every human clinical study on shilajit, zero serious adverse events have been reported. Trials monitoring blood pressure and pulse throughout found them stable. Blood safety labs in every published study remained within normal ranges.

Purity matters specifically in this context. Optimum shilajit comes from the Altai mountains, cold-pressed and purified, and every batch is independently tested by a third-party laboratory for heavy metals, mycotoxins, and Prop 65 compliance. We are a small, family-owned company out of Florida, and a real person answers when you reach out. Shilajit comes as a box of tablets, not a loose powder.

What this means for you

If you are in the post-menopausal years and watching cholesterol numbers move in the wrong direction, the mechanism behind that shift is not simply diet. Estrogen ran your lipid metabolism throughout your reproductive life. Its absence changes the equation in ways that salt restriction alone cannot address.

The research on shilajit works on those mechanisms. Not as a treatment, and not as a substitute for managing cardiovascular health through appropriate means, but as a studied approach to the vascular terrain that changes at menopause.

The Optimum Shilajit Trifecta combines purified shilajit from the Altai mountains with pearl powder and bamboo silica in a formula designed for women over 50. You can find it at https://www.liveoptimum.co/products/optimum-shilajit-trifecta.

Frequently asked questions

Does shilajit support heart health for women after menopause?

Human studies show shilajit improved cardiovascular markers across several trials. LDL fell, HDL rose, triglycerides fell, hsCRP fell, and endothelial function improved. No study has positioned shilajit as a treatment for cardiovascular disease. The evidence supports overall cardiovascular and vascular health.

Why does cardiovascular risk increase after menopause?

Estrogen ran lipid metabolism throughout a woman's reproductive years, keeping LDL lower, HDL higher, and supporting nitric oxide production in artery walls. When estrogen signaling drops at menopause, LDL climbs, HDL falls, triglycerides rise, and arteries stiffen. The cardiovascular risk that builds in the post-menopausal years is largely driven by this signaling shift.

What studies have tested shilajit for cardiovascular health?

A 12-week randomized controlled trial by Niranjan and colleagues found LDL fell 13 percent, total cholesterol fell 21 percent, triglycerides fell 16 percent, HDL rose 14 percent, and endothelial function improved. A 2003 Diabetes Care trial found oxidative damage cut by more than half in 30 days. A 45-day study in healthy adults found stable blood pressure with reduced lipids and improved antioxidant status.

Is shilajit safe for someone concerned about cardiovascular health?

Across every human clinical study on shilajit, zero serious adverse events have been reported. Trials that monitored blood pressure and pulse throughout found them stable. Optimum shilajit is third-party tested for heavy metals and mycotoxins and Prop 65 compliant.

Is shilajit a substitute for managing cardiovascular risk?

No. The evidence is on cardiovascular health markers in smaller trials. Anyone managing cholesterol or cardiovascular risk through other means should not change that approach based on supplement research. Shilajit addresses the underlying vascular terrain and is not positioned as a replacement for appropriate cardiovascular care.

References

1. Niranjan et al. Effect of purified shilajit on cardiovascular risk markers in type 2 diabetics. International Journal of Ayurvedic and Pharmaceutical Research. 2016. https://ijapr.in/index.php/ijapr/article/view/322
2. Saxena S, et al. A retrospective study on the effect of shilajit on lipid peroxidation. Journal of Ethnopharmacology. 2003. https://pubmed.ncbi.nlm.nih.gov/12882881/
3. Sharma P, et al. Evaluation of the safety and efficacy of shilajit. Ancient Science of Life. 2003. https://pubmed.ncbi.nlm.nih.gov/22557121/
4. Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia. Phytomedicine. 2022;105:154334. https://pubmed.ncbi.nlm.nih.gov/35933897/
5. Martinez et al. Effect of chromium, Phyllanthus emblica, and shilajit supplementation on cardiometabolic risk factors. 2025. https://pubmed.ncbi.nlm.nih.gov/40573153/